Cannabis business maintains positive adjusted EBITDA for
second consecutive quarter
(All amounts are in Canadian dollars unless otherwise
stated)
|
TORONTO, Dec. 22,
2022 /CNW/ - Shiny Health & Wellness Corp.
("Shiny Health" or the "Company") (TSXV: SNYB) today reported
financial results for its fiscal year 2023 third quarter for the
three and nine months ended October 31,
2022 (the "third quarter").
Third Quarter Highlights(1)
Three months
ended October 31, 2022 compared to
the three months ended October 31,
2021.
- Revenue increased by 31% to a $7.5
million with a system-wide revenue of $13.1 million(2)
- Gross profit increased by 31% to $2.8
million
- Sustained strong company-wide gross profit margin of 37.8%
unchanged year-over-year and compared to 36.1% quarter-over-quarter
(33.7% at cannabis store level versus 34.3% prior year)
- Operating & other expenses of $4.6
million (versus $2.4 million
prior year)
- Comprehensive net loss of $1.76
million
- Achieved positive enterprise Adjusted EBITDA(3) of
$0.265 million which includes:
-
- cannabis Adjusted EBITDA of $0.558
million;
- pharmacy Adjusted EBITDA of negative $0.193 million; and
- corporate Adjusted EBITDA of negative $0.100 million.
- Cash balance of $1.1 million as
at October 31, 2022
- Net working capital deficit of $2.2
million (current assets minus current liabilities)
-
- including contingent and non-cash derivative liabilities of
approximately $1 million
- ShinyBuddy Club Customer Loyalty Program grew to over 20,000
members
- Closed first pharmacy acquisition to advance health and
wellness retail strategy
"During the third quarter, our cannabis portfolio continued
generating higher revenues, maintained peer-leading profit margins,
and delivered positive adjusted EBITDA for the second consecutive
quarter. Concurrently, we established our initial footing into
health and wellness after closing our first pharmacy location to
differentiate our company from other cannabis retailers," said
Kevin Reed, Chairman and Chief
Executive Officer. "Going forward we will continue to focus on
leveraging our retail expertise and solid foundation in adult-use
cannabis to strengthen customer loyalty through our growing
membership program, growing sustainable profitability from our
existing cannabis stores, and building new customer relationships
through our pharmacy holdings."
Financial Highlights
Summary of consolidated financial information for the third
fiscal quarter of 2023 for the three and nine months ended
October 31, 2022 compared to the
three and nine months ended October 31,
2021.
|
Three Months Ended
October 31,
|
Nine Months Ended
October 31,
|
|
2022
|
2021
|
Change
|
2022
|
2021
|
Change
|
|
$
|
$
|
|
$
|
$
|
|
Revenue
|
7,463,267
|
5,714,579
|
30.6 %
|
22,776,467
|
15,453,771
|
47.4 %
|
Gross profit
|
2,819,045
|
2,157,247
|
30.6 %
|
8,449,164
|
5,820,965
|
45.2 %
|
Gross profit
margin
|
37.8 %
|
37.8 %
|
0.1 %
|
37.1 %
|
37.7 %
|
(0.6 %)
|
Total operating
expenses
|
3,704,155
|
1,968,818
|
88.1 %
|
11,961,160
|
4,740,118
|
152.3 %
|
Income (loss) from
operations
|
(885,110)
|
190,429
|
(464.8 %)
|
(3,511,996)
|
1,080,847
|
(324.9 %)
|
Total other income
(expenses)
|
(870,445)
|
(407,952)
|
(113,3 %)
|
(318,848)
|
(685,295)
|
53.5 %
|
Net comprehensive
income (loss)
|
(1,755,555)
|
(192,523)
|
(811.9 %)
|
(3,830,844)
|
270,552
|
(1515.9 %)
|
EBITDA(3)
|
(626,835)
|
421,773
|
(248.6 %)
|
(171,355)
|
1,246,347
|
(113.7 %)
|
Adjusted
EBITDA(3)
|
265,270
|
557,278
|
51.0 %
|
193,839
|
1,381,852
|
86.0 %
|
"Shiny Health & Wellness' third quarter results demonstrate
the continued strong performance of our adult-use retail cannabis
platform, while carefully navigating our extension into pharmacies
with the completion of our first acquisition," said Jude Pinto, Chief Financial Officer and Chief
Information Officer. "Our growth strategy is directly tied to the
buoyancy of debt and the equity capital market which dictates our
pace and form of growth in the coming period."
Quarterly Results
|
2023
|
|
Q3
|
Q2
|
Q1
|
Total sales
($)
|
7,463,267
|
7,738,680
|
7,574,520
|
Gross profit
($)
|
2,819,045
|
2,794,439
|
2,835,680
|
Profit (loss) from
operations ($)
|
(885,110)
|
(1,291,382)
|
(1,335,504)
|
Weighted average number
of stores (#)
|
28
|
31
|
29
|
Adjusted EBITDA
($)
|
265,270
|
(117,776)
|
46,345
|
Consolidated Performance
Three months ended
October 31, 2022 compared to the
three months ended October 31,
2021.
- Quarterly revenue increased by 31% to $7.5 million compared to the prior year period
primarily driven by the growth in Shiny Health's retail cannabis
network through new store openings and acquisitions in connection
with a business combination with Mihi Inc. completed January 2022. The average sales per store
decreased year over year consistent with province-wide trends
recently reported by the Ontario Cannabis Store. The ShinyBuddy
Data Program also contributed increased revenues with the
onboarding of several new Data Partners which contributed
$0.4 million in revenue for the
quarter compared to $0.3 million in
the prior year. $6.9 million of
revenue was generated from our cannabis operations.
- Gross profit increased by 31% to $2.8
million primarily driven by a store portfolio that doubled
and the addition of new Data Partners.
- Gross margin of 37.8% sustained year over year and slightly
higher quarter over quarter. Shiny Health's retail cannabis line of
business also sustained a strong store-level gross margin of 33.7%,
which is above industry average as the Company continued to focus
on a carefully curated product offering, adding higher margin
cannabis products, and managing costs.
- Total operating expenses increased to $3.7 million, an 88% increase primarily due to
the level of activity related to operating an expanded cannabis
store portfolio which grew from 14 stores to 28 stores, while
establishing scalable corporate and board functions to deliver
against strategic growth plans. Notable increases include insurance
and licensing fees related to directors and officers, marketing and
promotion expenses related to the larger store network, and
depreciation and amortization.
- Comprehensive net loss of $1.8
million, compared to a loss of $0.2
million in the prior year interim period, is segmented
across Company operations as follows:
-
- Operating income of $0.03 million
from the cannabis line of business due to higher revenues and gross
profit as the store portfolio doubled year over year, which also
contributed to an 83% decrease in income over the previous year
alongside incremental costs of operating more stores as a public
entity.
- Operating loss of $0.4 million
from the approximately one month of pharmacy operations
attributable to the start-up and acquisition costs to launch the
new segment for the Company.
- Operating loss of $0.5 million in
corporate costs includes expenses related to the management of a
public company that are not allocated to other segments.
- Company-wide Adjusted EBITDA(3) decreased to
$0.3 million, which is comprised of a
positive Adjusted EBITDA(3) of $0.6 million recorded by Shiny Health's cannabis
line of business, offset by negative Adjusted EBITDA of
$0.2 million and $0.1 million recorded by the Company's newly
established pharmacy initiative and corporate segment,
respectively.
Liquidity & Capital Management
- Cash balance of $1.1 million as
of October 31, 2022 compared to
$1.9 million as of
July 31, 2022, a change primarily
related to continued payments of one-time costs and repayment of
the FirePower loan.
- Net working capital deficit of $2.2
million (includes contingent and non-cash derivative
liabilities of approximately $1
million).
- Apart from growth capital, the Company expects to seek
additional capital (equity or debt) within the current period to
improve its near-term working capital position.
Retail Operations
Adult-use Cannabis Business
During the third quarter, Shiny Health opened one new cannabis
store in Stittsville, Ontario. At
October 31, 2022, management assessed
that there were indicators of impairment at its Pickering location
store as the economic performance of this location was
underperforming expectations. Subsequent to the third quarter, the
Company closed this location. An impairment charge of
$0.1 million was recognized for the
quarter based on the net recoverable value of property and
equipment. During the quarter, management also assessed that there
were indicators of impairment on some of its retail leases for
locations which are currently unused. An impairment charge of
$0.3 million was recognized in the
third quarter related to an ongoing annualized lease recovery of
$0.15 million in the second
quarter.
The Company currently has 27 corporate stores and 14 licensee
stores across Ontario and is
currently targeting to maintain a cannabis store portfolio of
between 25 to 35 corporate stores, plus 10 to 15 licensee cannabis
stores for its 2023 fiscal year-end.
Developing Pharmacy Business
Through its subsidiary mīhī Health & Wellness ("mīhī"), the
Company completed its previously announced acquisition of Cotton
Mill Pharmacy ("Cotton Mill"), on October 3,
2022. Cotton Mill is the first pharmacy acquisition in
furtherance of Shiny Health's plans to expand into health and
wellness.
In addition, Shiny Health has five additional pharmacy
candidates undergoing due diligence and continues to expand its
pipeline of purchase opportunities. To execute against this
pipeline, the Company has procured indicative proposals for debt
financing to co-fund the future pharmacy purchases. No
binding commitments have been entered into in relation to these
proposals, which are subject to due diligence and definitive
documentation and will also require that a proportionate share of
any future purchase price be funded from cash on hand or new equity
capital. The Company's ability to execute on any such acquisition
opportunities will depend on obtaining definitive commitments for
such debt financing and raising a corresponding amount of equity
capital, which require
that a portion of any future purchase price also be funded in
combination with equity capital. Therefore, the timeline to
acquiring the next location is largely subject to the
availability ability to raise the required
of capital on the open markets.
Corporate Update
Effective December 31, 2022,
Richard Espinos, co-founder and
director, will be resigning from the Board of Directors to focus on
his expanding professional commitments. Richard will remain
available to the Board and management team for ongoing strategic
guidance. On behalf of the directors, management team and
shareholders, Shiny Health thanks Mr. Espinos for his founding
contributions to the Company and wish him the best in his future
endeavours.
Consolidated Financial Statements
For further information, refer to Shiny Health's interim
condensed consolidated financial statements and related
management's discussion & analysis for the three and nine
months ended October 31, 2022 and
2021, which are available on the Company's corporate website at
www.shinyhealthandwellness.com and on SEDAR under the
Company's issuer profile at www.sedar.com.
Conference Call & Webcast
Management is hosting a live conference call and audio webcast
to review third quarter highlights with a question-and-answer
session as follows:
Date &
Time:
|
Friday, December 23,
2022 at 8:30 a.m. ET
|
Telephone:
|
Toll-free +
1-833-950-0062
|
|
Local or International
+1-226-828-7575
|
|
Please allow a few
minutes to be connected to the conference call.
|
Access
Code:
|
680441
|
Webcast:
|
Accessible on Shiny
Health's website at
www.shinyhealthandwellness.com/Q32023.
|
Note:
|
The slide presentation
will be available for download at
www.shinyhealthandwellness.com
|
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
(1)
|
The Company refers to
its unaudited consolidated interim financial statements for the
quarter ended October 31, 2022, which contains a going concern
qualification in Note 2 entitled Basis of Operation and Going
Concern.
|
|
|
(2)
|
System-wide revenue
includes revenue generated from Shiny Health's corporate-owned
stores, 14 licensee stores, and the ShinyBuddy Data Program. The
Company does not record licensee sales as revenues, however,
licensee fees are calculated based on 1% of licensee store
sales.
|
|
|
(3)
|
The Company defines
EBITDA and Adjusted EBITDA as per the table below. EBITDA and
Adjusted EBITDA are non-IFRS financial measures that do not have
standardized meanings prescribed under IFRS and may not be
comparable to similar measures disclosed by other issuers.
Management calculates "EBITDA" for a financial period as the
Company's income (loss) for the period, as determined in accordance
with IFRS, before accretion and interest, tax, and depreciation and
amortization, and calculates "Adjusted EBITDA" for a financial
period as the EBITDA for the period after adjusting to remove
impairment, loss on settlement of loan, gain on revaluation of
derivative liability, gain on change in fair value, share-based
compensation and strategic one-time cost.
|
|
|
|
Management uses EBITDA
and Adjusted EBITDA to assess the Company's ability to generate
cash from operations, and the Company believes them to be useful
measures for this purpose. They are, however, supplementary
information only and should not be relied upon for comparative or
investment purposes. Readers must not consider non-IFRS measures in
isolation or as a substitute for analysis of the Company's
financial results as reported under IFRS. EBITDA and Adjusted
EBITDA are not, and must not be construed as alternatives to, net
income (loss) or cash flow from operating activities as determined
under IFRS.
|
|
|
|
The following table
reconciles net (loss) income for the periods indicated to EBITDA
and Adjusted EBITDA, respectively:
|
|
Three months ended October 31
|
Nine months ended October 31
|
|
2022
|
2021
|
Change
|
2022
|
2021
|
Change
|
|
$
|
$
|
|
$
|
$
|
|
Total Comprehensive
loss (income)
|
1,641,284
|
192,523
|
725.5 %
|
3,670,826
|
(270,552)
|
1456.8 %
|
Income tax (recovery)
expense
|
-
|
25,000
|
(100.0 %)
|
-
|
125,000
|
(100.0 %)
|
Finance
costs
|
317,394
|
275,053
|
36.5 %
|
1,056,158
|
554,921
|
90.32 %
|
Depreciation &
amortization
|
817,055
|
314,243
|
160.0 %
|
2,443,313
|
836,978
|
191.9 %
|
EBITDA
|
(626,835)
|
421,773
|
(248.6 %)
|
(171,355)
|
1,246,347
|
(113.7 %)
|
Impairment
|
433,654
|
135,505
|
220.0 %
|
981,615
|
135,505
|
624.4 %
|
One-time strategic
costs
|
244,769
|
-
|
100.0 %
|
998,353
|
-
|
100.0 %
|
Revaluation loss (gain)
on derivative liability
|
111,951
|
-
|
100.0 %
|
(2,920,999)
|
-
|
(100.0 %)
|
Loss on extinguishment
of loan
|
-
|
-
|
-
|
1,267,726
|
-
|
100.0 %
|
Share-Based
compensation
|
89,710
|
-
|
100.0 %
|
265,055
|
-
|
100.0 %
|
Gain on change in fair
value
|
12,021
|
-
|
100.0 %
|
(226,556)
|
-
|
100.0 %
|
Total Adjusted
EBITDA
|
265,270
|
557,278
|
(52.4 %)
|
193,839
|
1,381,852
|
(86.0 %)
|
Footnotes to table above:
|
Cash outflow for the lease liabilities for the
three-month period ended October 31, 2022 were $468,728 and
$1,388,584 for the nine-month period ended October 31,
2022.
|
Cash outflow for the lease liabilities for the
three-month period ended October 31, 2021 were $204,161 and
$532,760 for the nine-month period ended October 31,
2021.
|
For the three-month period ended October 31, 2022,
adjusted EBITDA was $0.265 million, comprised of $0.558 million
from the cannabis operations, and ($0.193) million from the
pharmacy operations and ($0.100) million from corporate items not
allocated to a segment.
|
|
For the nine-month period ended October 31, 2022,
adjusted EBITDA was $0.194 million, comprised of $1.427 million
from the cannabis operations, ($0.904) million from the pharmacy
operations and ($0.329) million from corporate items not allocated
to a segment.
|
|
The following table provides details about the EBITDA
and adjusted EBITDA by segment:
|
|
Cannabis
|
Pharmacy
|
Corporate
|
Total
|
For the three-month period
ended October 31,
|
2022
|
2021
|
2022
|
2021
|
2022
|
2021
|
2022
|
2021
|
$
|
$
|
$
|
$
|
$
|
$
|
$
|
$
|
Total
Comprehensive loss
(income)
|
1,096,901
|
192,523
|
453,262
|
-
|
211,121
|
-
|
1,761,284
|
192,523
|
Income tax (recovery)
expense
|
-
|
25,000
|
-
|
-
|
-
|
-
|
-
|
25,000
|
Finance
costs
|
308,177
|
275,053
|
9,217
|
-
|
-
|
-
|
317,394
|
275,053
|
Depreciation &
amortization
|
810,445
|
314,243
|
6,610
|
-
|
|
-
|
817,055
|
314,243
|
EBITDA
|
21,721
|
421,773
|
(437,435)
|
-
|
(211,121)
|
-
|
(626,835)
|
421,773
|
Impairment
|
433,654
|
135,505
|
-
|
-
|
-
|
-
|
433,654
|
135,505
|
One-time strategic
costs
|
-
|
-
|
244,769
|
-
|
-
|
-
|
244,769
|
-
|
Revaluation loss (gain)
on
derivative liability
|
41,467
|
-
|
-
|
-
|
70,484
|
-
|
111,951
|
-
|
Loss on extinguishment
of loan
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Share-Based
compensation
|
-
|
-
|
-
|
-
|
89,710
|
-
|
89,710
|
-
|
Gain on change in fair
value
|
61,460
|
-
|
-
|
-
|
(49,439)
|
-
|
12,021
|
-
|
Adjusted EBITDA
|
558,302
|
557,278
|
(192,666)
|
-
|
(100,366)
|
-
|
265,270
|
557,278
|
|
Cannabis
|
Pharmacy
|
Corporate
|
Total
|
For the nine-month period
ended October 31,
|
2022
|
2021
|
2022
|
2021
|
2022
|
2021
|
2022
|
2021
|
$
|
$
|
$
|
$
|
$
|
$
|
$
|
$
|
Other
Comprehensive loss
(income)
|
4,336,756
|
(270,552)
|
1,164,186
|
-
|
(1,830,116)
|
-
|
3,670,826
|
(270,552)
|
Income tax (recovery)
expense
|
-
|
125,000
|
-
|
-
|
-
|
-
|
-
|
125,000
|
Finance
costs
|
1,046,941
|
554,921
|
9,217
|
-
|
-
|
-
|
1,056,158
|
554,921
|
Depreciation &
amortization
|
2,436,703
|
836,978
|
6,610
|
-
|
-
|
-
|
2,443,313
|
836,978
|
EBITDA
|
(853,112)
|
1,246,347
|
(1,148,359)
|
-
|
1,830,116
|
-
|
(171,355)
|
1,246,347
|
Impairment
|
981,615
|
135,505
|
-
|
|
-
|
|
981,615
|
135,505
|
One-time strategic
costs
|
753,584
|
-
|
244,769
|
|
|
|
998,353
|
-
|
Revaluation loss (gain)
on
derivative liability
|
(546,132)
|
-
|
-
|
-
|
(2,374,867)
|
-
|
(2,920.999)
|
-
|
Loss on extinguishment
of loan
|
1,267,726
|
-
|
-
|
-
|
-
|
-
|
1,267,726
|
-
|
Share-Based
compensation
|
-
|
-
|
-
|
-
|
265,055
|
-
|
265,055
|
-
|
Gain on change in fair
value
|
(177,116)
|
-
|
-
|
-
|
(49,440)
|
-
|
(226,556)
|
-
|
Adjusted EBITDA
|
1,426,565
|
1,381,852
|
(903,590)
|
|
(329,136)
|
|
193,839
|
1,381,852
|
The following table provides details about the
one-time strategic costs:
|
|
Three months ended October 31
|
Nine months ended October 31
|
|
2022
|
2021
|
Change
|
2022
|
2021
|
Change
|
|
$
|
$
|
|
$
|
$
|
|
Acquisition and
strategic initiative professional fees
|
244,769
|
-
|
100.0 %
|
896,685
|
-
|
100.0 %
|
Restructuration and
other costs
|
-
|
-
|
-
|
101,668
|
-
|
100.0 %
|
Total
|
244,769
|
-
|
-
|
998,353
|
-
|
100.0 %
|
About Shiny Health & Wellness
Shiny Health & Wellness Corp. is on a mission to help people
never settle, live fully by being a trusted source for health and
wellness solutions and services. The Company recently broadened its
retail growth strategy beyond adult-use cannabis by establishing
mīhī Health & Wellness, a new line of business focused on
building a network of community pharmacies across Ontario. Striving to provide a more diverse
and accessible cannabis experience for adult consumers, the Company
also operates ShinyBud Cannabis Co., a well-established brand in
Ontario strategically located in
markets less saturated with cannabis retailers. The Company's board
and management team hold extensive retail operating experience, a
key competitive differentiator in leading its growth strategy.
Shiny Health trades on the TSX Venture Exchange (TSXV) under the
ticker symbol SNYB. For more information, please visit
www.shinyhealthandwellness.com.
Cautionary Statement Regarding Forward-Looking
Information
This news release contains statements ("forward-looking
statements") that constitute forward-looking information within the
meaning of applicable Canadian securities laws.
Forward-looking statements relate to future performance, events,
outcomes or circumstances or are otherwise prospective in nature,
are based upon internal assumptions, opinions, estimates, plans,
beliefs and expectations about future conditions, developments and
courses of action. They are inherently uncertain as they
depend on the accuracy of such assumptions, opinions, estimates,
plans, beliefs and expectations, which cannot be assured, and are
subject to known and unknown risks and uncertainties that will
cause actual results to differ from those indicated, suggested or
anticipated in the forward-looking statements. The
differences may be material and adverse to the Company.
All statements other than statements of current or historical
fact constitute forward-looking statements. Forward-looking
statements are often, but not always, identified by the use of
words such as "anticipate", "believe", "expect", "intend", "seek",
"plan", "aim", "budget", "forecast", "target", "estimate",
"objective", "propose", "predict", "potential", "project",
"continue", "pursue", "may", "will", "might", "should", "could" or
similar words suggesting future outcomes or events or statements
regarding an outlook.
Without limiting the foregoing, this news release contains
forward-looking statements pertaining to: Shiny Health's business
strategy and growth potential in respect of both its retail
cannabis business and expansion into the pharmacy sector; target
numbers of corporate and licensed cannabis stores for 2023 fiscal
year-end; and the Company's designs on raising additional
capital.
Forward-looking statements, and the
underlying assumptions, opinions, estimates, plans, beliefs and
expectations on which they are based, are inherently uncertain as
they depend on future conditions, developments and courses of
action that may or not occur or come to be. There can be no
assurance that the underlying assumptions, opinions, estimates,
plans, beliefs and expectations will prove to be correct and,
accordingly, no assurance that the future performance, events,
outcomes or circumstances expressed or implied in the
forward-looking statements herein will occur or be realized.
Actual results will differ, and the differences may be material and
adverse to the Company.
In addition to the other factors and assumptions that may be
identified herein, material factors and assumptions used to develop
the forward-looking statements contained in this news release
include, among other things, assumptions, opinions, estimates,
plans, beliefs and expectations regarding: the effectiveness of our
retail cannabis and pharmacy strategy; our ability to identify and
consummate accretive acquisitions, expand our store network within
budgeted costs and timelines, drive same-store sales growth,
improve margins and generate new revenue streams; our ability to
obtain additional licenses, authorizations and regulatory approvals
(including any required approvals of the TSX Venture Exchange) as
and when required to fit our growth and business plan; the size of
the cannabis retail market and estimated portion currently
unserved, and the migration of customers from the illicit market to
legal market; our ability to capture additional market share; our
ability to attract franchisees to the ShinyBud brand and model, and
the terms of franchise arrangements; the number, type and locations
of new stores; the applicability and relevance of our experience in
existing centers and locations to new centers and locations; our
ability to influence our customer purchase decisions; our ability
to maintain, enhance, and grow our appeal within our addressable
market, and to customize products and inventory for the market that
resonate with our target customer base; our ability to source
product that is key to our menu offerings; our ability to leverage
our landlord network and build a flexible lease portfolio; our
ability to manage costs and drive operating efficiencies; our
ability to retain key management and non-management personnel, and
to hire, train and motivate staff; the availability of capital, and
our ability to obtain any required external financing on acceptable
terms; our competitive strengths and the impact of competition; the
accuracy of our financial models; trends in the retail cannabis and
pharmacy sectors; the regulatory framework applicable to the retail
cannabis and pharmacy industries in Canada, and the direction of any changes in
that framework and underlying laws; and general economic, political
and social conditions affecting the retail cannabis and pharmacy
businesses.
Forward-looking statements are subject to known and unknown
risks, uncertainties and other factors that will cause actual
results to differ from those indicated, suggested or anticipated in
the forward-looking statements, and the differences may be
material. Readers must therefore exercise caution and not
rely on forward-looking statements, which rest on assumptions,
opinions, estimates, plans, beliefs and expectations as of the date
made that may change, and are in any event not a guarantee of
future performance or a promise of any future outcomes. We
believe such risks, uncertainties and other factors to include,
without limitation, the following: risks associated with the retail
cannabis and pharmacy industries generally; adverse changes in the
general economic or market conditions, and to customer spending in
the centers where we operate; unforeseen obstacles that prevent,
delay or otherwise compromise the execution of our growth plan;
inability to obtain additional licenses and authorizations (and
other needed regulatory approvals) as and when required to fit our
growth and business plan; ineffectively managing our growth;
failure to secure desirable store locations; inability to secure
leasehold premises for new stores on acceptable terms, risks
associated with leasing retail space; adverse changes to the
regulatory framework applicable to the retail cannabis and pharmacy
industries in Canada, or to other
laws and regulations affecting our business (including taxes);
unanticipated diminishment of the Shiny Health or mīhī brands or
any trademark protections; negative publicity for us or our
business; marketing strategies that are less successful than
expected; our highly competitive industry and the relative size and
resources of some of our competitors; being unable to successfully
open and operate new stores; profitability erosion from unexpected
cost increases; slower profitability of new stores; failure to
identify, recruit and contract with a sufficient number of
qualified franchise partners; lack of access to capital to fund
expansion, or more costly financing terms than expected; a data
security breach that results in improper use or disclosure of
confidential customer or employee information; risks associated
with industry consolidation; loss of key management or other key
personnel, or unexpected difficulty in attracting, training and/or
motivating staff as necessary to execute our business plan;
unexpected challenges in growing sales or connecting with our
customer base; inability to meet other financial targets; any
material claims made against us, which could result in litigation;
insolvency risks with parties with whom we do business; increased
expenses of being a public company; the forward-looking statements
contained in this presentation proving to be inaccurate and
incorrect despite there being a reasonable basis therefor at the
time they were made; and such other risks, uncertainties and other
factors as may be discussed or set out from time-to-time in Shiny
Health's public disclosure documents (including, without
limitation, those risks identified in the Company's management's
discussion and analysis filed by the Company with applicable
securities regulatory authorities in Canada and available under its issuer profile
on SEDAR at www.sedar.com).
With respect to the Company's designs on raising capital, there
can be no assurance that any such capital will be available.
If capital is available there can be no assurance regarding
the cost and other terms that might be demanded by financing
sources, or the effect thereof on the Company or existing
stakeholders.
The foregoing lists of material assumptions and risks,
uncertainties and other factors are not exhaustive. The
forward-looking statements contained herein speak only as of the
date of this news release. The Company disclaims any intention,
obligation or undertaking to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, or to explain any difference between actual results
and those indicated, suggested or anticipated in any forward
looking statements, except as may be required under applicable
securities laws.
All forward-looking statements contained in this news release
and in any related reports or disclosures filed or issued by the
Company, or made by the Company's directors, officers and other
persons authorized to speak on its behalf regarding the subject
matter hereof, are expressly qualified by this cautionary
statement.
SOURCE Shiny Health & Wellness Corp.